---
title: "Harvard Bioscience, Inc. (HBIO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HBIO.US.md"
symbol: "HBIO.US"
name: "Harvard Bioscience, Inc."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-20T08:06:43.588Z"
locales:
  - [en](https://longbridge.com/en/quote/HBIO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HBIO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HBIO.US.md)
---

# Harvard Bioscience, Inc. (HBIO.US)

## Company Overview

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Website | [www.harvardbioscience.com](https://www.harvardbioscience.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: D (0.64)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 55 / 59 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -6.42% |  |
| Net Profit YoY | 83.15% |  |
| P/B Ratio | 2.23 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 22404664.89 |  |
| Revenue | 85531000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -78.65% | E |
| Profit Margin | -11.44% | D |
| Gross Margin | 58.99% | B |
| Revenue YoY | -6.42% | D |
| Net Profit YoY | 83.15% | A |
| Total Assets YoY | -2.33% | D |
| Net Assets YoY | -32.28% | E |
| Cash Flow Margin | -31.49% | E |
| OCF YoY | -6.42% | D |
| Turnover | 1.08 | A |
| Gearing Ratio | 87.11% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Harvard Bioscience, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-6.42%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "83.15%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.23",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "22404664.89",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "85531000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-78.65%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-11.44%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "58.99%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-6.42%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "83.15%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.33%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-32.28%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-31.49%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-6.42%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "1.08",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "87.11%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.29 | 33/59 | - | - | - |
| PB | 2.23 | 24/59 | 2.08 | 1.63 | 1.32 |
| PS (TTM) | 0.26 | 3/59 | 0.32 | 0.26 | 0.22 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A |
| 02 | Agilent Tech (A.US) | A | C | B | C | C | B |
| 03 | West Pharmaceutical (WST.US) | B | B | B | B | B | B |
| 04 | Illumina (ILMN.US) | A | C | B | D | C | B |
| 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 50% |
| Hold | 1 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.01 |
| Highest Target | 6.00 |
| Lowest Target | 6.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/HBIO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/HBIO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/HBIO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/HBIO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**